Zealand becomes a lesson in the rigors of commercialization as a slow launch triggers 90% staff cut, CEO exit BD’s medical segment president Mas set to retire after 30 years California auditors outline rampant fraud endangering LA County hospice patients UPDATE: After FDA hold, CytoDyn will appeal for pharma partnerships to save leronlimab Synchron’s brain-computer interface implant deemed safe after 1 year in ALS patients HRSA calls for Boehringer Ingelheim to be fined over 340B contract pharmacy restrictions Reuniting the band: Former Merck CEO follows 3 former colleagues to Eikon Bayer sheds some sites in €2B push to expand next-gen manufacturing capabilities AHA launches Health Equity Roadmap, an interactive program for members to build out their equity efforts Vertex gets proof-of-concept for non-opioid painkiller, clearing way for pivotal studies Fresenius Kabi picks up smart infusion pump developer Ivenix plus a stake in biosimilar maker mAbxience Feds probe ring of counterfeit HIV meds targeting Gilead, GlaxoSmithKline and Johnson & Johnson: report 2 gene editing biotechs team up to improve on delivery with $45 upfront Featured Story | By Ben Adams It wasn’t supposed to be this way. Zealand Pharma should be in the honeymoon glow of its first drug launch with an approval less than a year ago. Instead, it's losing its CEO and shedding 90% of its U.S. workforce. read more |
| |
|---|
|
Top Stories By Andrea Park After spending nearly half his life and the majority of his career with the company, Alberto Mas has made plans to retire from BD later this year—just shy of his 30th anniversary there. read more By Dave Muoio Among the evidence of a "large and organized effort to defraud the Medicare and Medi-Cal" hospice programs cited by auditors was a single building containing over 150 licensed hospice and home health agencies. read more By Annalee Armstrong With CytoDyn's lead drug on FDA clinical hold, the troubled biotech will go searching for partners to rescue key programs and keep afloat. Meanwhile, the board is actively searching for a new CEO to replace Nader Pourhassan, Ph.D., who was ousted in January. read more By Andrea Park New results from Synchron’s first human study of its brain-computer interface system found that one year after the device’s placement, none of the four participants had experienced any adverse events that led to disability or death. read more By Robert King HRSA is pushing for Boehringer Ingelheim to be fined for its decision to cut off sales of 340B-discounted products to contract pharmacies. read more By Max Bayer Eikon Therapeutics continues to reunite former Merck colleagues, this time adding former CEO Ken Frazier to its board. Frazier's appointment is the third former Merck colleague to join this year after the company's former R&D president Roger Perlmutter was tapped as CEO in May 2021. read more By Joseph Keenan German pharma giant Bayer plans to spend 2 billion euros ($2.2 billion) over the next three years to upgrade its manufacturing and supply chain capabilities as it dives deeper into cell and gene therapies. As part of the effort, the company is selling certain sites to outside partners. read more By Anastassia Gliadkovskaya The road map is available free to members and consists of an assessment, a customized action plan and a virtual community of peers to discuss the work. read more By Annalee Armstrong Vertex’s non-opioid painkiller eased pain intensity after surgery in two phase 2 clinical trials, giving the company the proof-of-concept needed to advance to a pivotal study in the second half of this year. read more By Conor Hale The drug producer Fresenius Kabi is taking its first steps under a new strategy to bolster its intravenous drug offerings. read more By Kevin Dunleavy The Department of Justice is said to be investigating reports of distributors and pharmacies selling counterfeit versions of HIV drugs from several companies including Gilead, GlaxoSmithKline and Johnson & Johnson. read more By Gabrielle Masson Myeloid Therapeutics and Prime Medicine have signed an exclusive option and research collaboration to develop Myeloid’s RNA-based gene-editing technology, dubbed “RetroT." Prime is shelling out $45 million upfront for the opportunity. read more |
